Journal article
Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
Biomedicines, Vol.9(1), 70
01/12/2021
DOI: 10.3390/biomedicines9010070
PMCID: PMC7828137
PMID: 33445667
Abstract
Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and strategies. The use of mithramycin, an antineoplastic antibiotic, has been previously limited by its narrow therapeutic window. Recent advances in semisynthetic methods have led to mithramycin analogs with improved pharmacological profiles. Mithramycin inhibits the activity of the transcription factor Sp1, which is closely linked with ovarian tumorigenesis and platinum-resistance. This article summarizes recent clinical developments related to mithramycin and postulates a role for the use of mithramycin, or its analog, in the treatment of platinum-resistant ovarian cancer.
Details
- Title: Subtitle
- Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
- Creators
- David Schweer - Markey Cancer CenterJ Robert McCorkle - University of KentuckyJurgen Rohr - University of KentuckyOleg V Tsodikov - University of KentuckyFrederick Ueland - University of KentuckyJill Kolesar - University of Kentucky
- Resource Type
- Journal article
- Publication Details
- Biomedicines, Vol.9(1), 70
- DOI
- 10.3390/biomedicines9010070
- PMID
- 33445667
- PMCID
- PMC7828137
- ISSN
- 2227-9059
- eISSN
- 2227-9059
- Grant note
- T32 CA160003 / NCI NIH HHS T32CA160003 / NIH Training Grant P30 CA177558 / NCI NIH HHS
- Language
- English
- Date published
- 01/12/2021
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984695799702771
Metrics
2 Record Views